Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Mereo BioPharma (MREO) EBT (2023 - 2025)

Mereo BioPharma (MREO) has disclosed EBT for 3 consecutive years, with -$7.4 million as the latest value for Q4 2025.

  • Quarterly EBT fell 4.33% to -$7.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$41.9 million through Dec 2025, up 3.18% year-over-year, with the annual reading at -$41.9 million for FY2025, 3.18% up from the prior year.
  • EBT for Q4 2025 was -$7.4 million at Mereo BioPharma, down from -$7.0 million in the prior quarter.
  • The five-year high for EBT was -$1.8 million in Q2 2023, with the low at -$15.0 million in Q3 2024.
  • Average EBT over 3 years is -$9.6 million, with a median of -$9.3 million recorded in 2023.
  • The sharpest move saw EBT crashed 599.89% in 2024, then skyrocketed 53.18% in 2025.
  • Over 3 years, EBT stood at -$9.6 million in 2023, then grew by 26.92% to -$7.0 million in 2024, then dropped by 4.33% to -$7.4 million in 2025.
  • According to Business Quant data, EBT over the past three periods came in at -$7.4 million, -$7.0 million, and -$14.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.